▶ Full Post Text
**TL;DR:** Abbott is a $44B revenue healthcare company growing 7-8% organically with a $7.6B CGM franchise (FreeStyle Libre) growing 17%+ annually, a cardiac devices pipeline full of first-in-class products, a fortress balance sheet (AA- rated), and 54 consecutive years of dividend increases. At ~$110/share (~19x forward earnings, ~23x owner earnings), you're getting a magnificent business at a price that actually offers margin of safety. I'm buying because the business is exceptional, the growth runway is long, and at this price the math points to 13-16% annual compounding. Here's the full case, including every risk I see.
---
## The Investment Thesis in 60 Seconds
Abbott has four healthcare businesses. The standout is Medical Devices (48% of revenue), anchored by FreeStyle Libre — a continuous glucose monitor franchise with 5M+ users, 17% annual growth, and only one real competitor. The rest of the company (Diagnostics, Nutrition, Pharmaceuticals) generates steady cash that funds the growth engine. The balance sheet is a fortress. Management is proven. Every segment serves essential human needs that don't disappear in a recession.
At ~$110/share, you're paying ~19x forward earnings. For a business of this quality, that's genuinely attractive. Abbott dropped after a Q4 2025 revenue miss, and the market handed you a chance to own one of healthcare's best compounders at a price that actually works. The 52-week high is $141. You're buying 22% below that.
Magnificent businesses at reasonable prices don't stay that way forever. The underlying growth engine hasn't changed — just the price tag.
---
## What Does Abbott Actually Do?
**1. Medical Devices (48% of revenue — $21.4B) — The Growth Engine**
Two major franchises:
- **FreeStyle Libre CGM:** ~$7.6B in revenue, growing 17%+ annually. Small sensors worn on the arm that continuously track blood sugar, replacing painful finger pricks. Over 5 million users worldwide. Only Dexcom competes seriously. Abbott recently got FDA clearance for over-the-counter versions (Lingo for wellness, Libre Rio for diabetics without prescriptions), expanding the addressable market from diabetic patients to health-conscious consumers. At this growth rate, CGM alone becomes a $10B+ business by 2027.
- **Cardiac Devices:** $9.4B across electrophysiology, pacemakers, heart valves, and heart failure devices. Five of seven sub-segments grew double digits in 2025. Key products: AVEIR (world's first dual-chamber leadless pacemaker), Volt (pulsed field ablation for atrial fibrillation), Tendyne (first-in-class mitral valve replacement). Each product took years and hundreds of millions to develop. Competitors can't shortcut that.
Once a doctor prescribes a Libre sensor or implants an Abbott device, the patient stays in Abbott's ecosystem. Sensors need replacing. Devices need servicing. Recurring revenue with high switching costs.
**2. Diagnostics (20% of revenue — $8.9B) — The Cash Cow**
Looks like it's shrinking — it's not. COVID testing went from $1.6B in 2023 to $300M in 2025. That distortion is now over. The real business underneath is Core Lab Diagnostics ($5.4B): Abbott's Alinity analyzers sit in hospital labs running blood tests. Once installed (a 2-3 year qualification process), hospitals buy Abbott's reagents for years. Razor/razorblade economics. Only Roche and Siemens compete at scale. U.S. Core Lab grew 7-8% in 2025.
**3. Nutrition (19% of revenue — $8.5B) — The Steady Hand**
Similac (#1 U.S. infant formula), Ensure (market leader in adult nutrition), Glucerna (diabetic nutrition that pairs with Libre). Only three major competitors in infant formula and FDA manufacturing requirements are extremely strict. The 2022 recall is fully behind them. Low single-digit growth, high reliability.
**4. Established Pharmaceuticals (12% of revenue — $5.5B) — The Emerging Markets Cash Machine**
Zero U.S. sales. Branded generics sold in India, Latin America, the Middle East, and Southeast Asia. Grew 7-10% organically every year from 2023-2025. Requires minimal R&D. Throws off cash that funds the growth segments. Rides the structural tailwind of rising healthcare spending in developing economies.
---
## The Numbers
**Revenue — The COVID Headwind Is Gone:**
| Year | Revenue | Base Organic Growth | COVID Testing |
|------|---------|-------------------|---------------|
| 2023 | $40.1B | +11.6% | $1.59B |
| 2024 | $42.0B | +9.6% | $0.75B |
| 2025 | $44.3B | +6.7% | $0.30B |
| 2026 (guided) | ~$47B | +6.5-7.5% | Negligible |
$1.3B in COVID revenue vanished over three years. Total revenue still grew. The underlying engine is now fully visible, and it's strong.
**Earnings — Steady Compounding:**
| Year | Adjusted EPS | Growth |
|------|-------------|--------|
| 2023 | $4.44 | — |
| 2024 | $4.67 | +5.2% |
| 2025 | $5.15 | +10.3% |
| 2026 (guided) | $5.55-$5.80 | ~10% |
From $4.44 to a guided $5.68 midpoint in three years — 28% cumulative growth, ~8.5% CAGR, accelerating as COVID noise clears. Margins are expanding too: adjusted operating margin went from ~22.5% in 2023 to ~23.5% in 2025 as the revenue mix shifts toward higher-margin Medical Devices.
**Owner Earnings — What Shareholders Actually Get:**
After subtracting the capital Abbott must reinvest to maintain its competitive position (R&D + capital expenditures), the business generates **~$8.4B per year in true economic earnings**, or **~$4.79 per share**. At ~$110, that's **~23x owner earnings** — a reasonable multiple for a business with this durability.
**Balance Sheet — The Fortress:**
- $7.5B cash, $12.9B total debt, only $5.4B net debt
- Could repay all net debt in 8 months of operating cash flow
- 43x interest coverage — earnings cover interest payments 43 times over
- AA-/Aa3 credit rating — among the highest in all of healthcare
- 54 consecutive years of dividend increases, 408 consecutive quarterly dividends
- $7B share repurchase program authorized October 2024
---
## Why This Business Is Nearly Impossible to Attack
- **FreeStyle Libre:** A competitor needs $200M+ and 5-7 years of clinical trials for FDA approval, then must convince 5 million patients to leave a system integrated into their daily routine and their insulin pumps. Only Dexcom competes.
- **Core Lab Diagnostics:** Hospitals would need to rip out installed analyzers and spend 2-3 years validating a new platform. Only Roche and Siemens play here.
- **Cardiac Devices:** Devices implanted in human hearts face the highest regulatory bar in medicine, plus decades of surgeon training relationships. Only Edwards Lifesciences and Medtronic are real peers.
- **U.S. Infant Formula:** FDA manufacturing approval is extremely stringent. Pediatrician trust is built over decades. Only Enfamil and Nestle compete.
These advantages are structural and self-reinforcing. FreeStyle Libre gets stronger as more users generate data, more pump manufacturers integrate, and more doctors prescribe it. The moat widens over time.
---
## Management
CEO Robert Ford has handled three major stress tests:
1. **COVID windfall:** Billions in temporary testing revenue. No empire-building, no wasteful acquisitions. Cash flowed to shareholders while the base pipeline got funded. Disciplined capital allocation under pressure.
2. **Infant formula recall (2022):** Could have permanently damaged Similac. Abbott reclaimed #1 U.S. market share within a year.
3. **Capital allocation:** $1.5B in debt repaid in 2025. Consistent dividend raises. 15+ new product approvals in 2024 alone. Guidance has been met or beaten throughout this entire period.
**One concern:** Abbott announced a pending acquisition of Exact Sciences (cancer diagnostics) in late 2025, expected to close mid-2026. This adds integration risk and could temporarily distract from the core Medical Devices growth story. Worth monitoring, but Ford has earned the benefit of the doubt.
---
## The Risks — Eyes Wide Open
I'm recommending a buy, not ignoring the risks. Here's what could go wrong:
**1. NEC Litigation (moderate-high):** Lawsuits allege Abbott's preterm infant formula caused necrotizing enterocolitis. One jury awarded $495M (on appeal). However, three federal bellwether cases in 2025 ruled in Abbott's favor via summary judgment. The legal trend is moving Abbott's way, but a string of adverse verdicts could create aggregate liability in the billions.
**2. IRS Tax Dispute ($1.05B):** The IRS is challenging income allocation between U.S. and foreign operations for 2017-2020. All contested in Tax Court. Even worst case, $1.05B is roughly 12% of one year's operating cash flow — painful but not existential.
**3. China Pricing Pressure:** Government volume-based procurement is compressing Diagnostics pricing in China. This is a structural headwind, but Diagnostics is only 20% of total revenue and China is a subset of that.
**4. Exact Sciences Acquisition:** Integration complexity is real. If execution stumbles, it could weigh on earnings and management attention in 2026-2027.
**5. Tariffs:** Abbott manufactures globally across 160+ countries. Escalating trade tensions could compress margins.
**6. Further Downside:** Even at ~19x forward earnings, a broad market selloff or growth disappointment could push the stock lower. The 52-week low is $105. If Medical Devices growth decelerates, there's another 5-10% of downside before the valuation floor gets truly compelling.
None of these risks threaten the long-term business. The balance sheet can absorb litigation losses. The growth engine (Medical Devices) is independent of China or tariff issues. But any of them could create short-term volatility — which, if you're already an owner, becomes a chance to add more.
---
## Valuation — A Rare Chance to Buy Quality at a Reasonable Price
Here's exactly what you're paying and what you're getting.
| Metric | Value |
|--------|-------|
| Current Price | ~$110 |
| FY2025 Adjusted EPS | $5.15 |
| FY2026 Guided EPS (midpoint) | $5.68 |
| P/E on 2025 earnings | ~21x |
| P/E on 2026 guidance | ~19x |
| Owner Earnings/Share | ~$4.79 |
| Price/Owner Earnings | ~23x |
| Dividend Yield | ~2.3% |
| 52-Week High | $141 |
| Distance from High | -22% |
**What your returns look like from here:**
Abbott is guiding for 10% EPS growth in 2026, and the pipeline supports similar growth for several years beyond that. If you buy at $110 and the company delivers 10-12% annual earnings growth for the next decade, your total return comes from three sources:
1. **Earnings growth:** 10-12% annually, driving the stock price higher over time
2. **Dividend income:** 2.3% current yield, growing 7%+ per year (today's $2.52/share becomes ~$5/share in 10 years)
3. **Multiple expansion:** At 19x forward earnings, Abbott is trading below its historical average for a business of this quality. If the multiple reverts even modestly to 22-23x, that alone adds 15-20% upside
Add those together and you're looking at **13-16% total annual returns** — with realistic upside if the multiple normalizes. Compare that to a 10-year Treasury at ~4.5% or the S&P 500's historical ~10%. Abbott at 13-16% with lower business risk than most growth stocks and a growing dividend is a strong place to put capital.
**The intrinsic value math:**
If Abbott grows earnings at 10% annually for 10 years, EPS goes from $5.15 to $13.36. Apply an 18x exit multiple and discount back at 10%, you get roughly **$122-125 per share** including dividends. At 12% growth (Medical Devices accelerating), the number moves to **$140-145**. You're buying at $110 — that's a 10-30% margin of safety depending on your growth assumption. This is the discount that rarely shows up on a business this good.
**Why now?**
Abbott dropped after a Q4 2025 revenue miss ($11.46B vs. expectations). The stock fell ~9% in a single session. But the miss was narrow, EPS met estimates at $1.50, and full-year 2026 guidance came in strong at $5.55-$5.80. The market punished the stock on a single quarter while the multi-year growth story — CGM expansion, cardiac pipeline, emerging market tailwinds — remains fully intact. That's exactly the kind of overreaction that creates buying opportunities in high-quality names.
---
## The Bottom Line — Why I'm Buying
Abbott is one of the best healthcare businesses. Here's what you're getting:
- A $7.6B CGM franchise growing 17%+ with a path to $10B+ and expanding into OTC markets
- A cardiac devices pipeline with multiple first-in-class products, each a multi-year growth driver
- Four segments serving essential human needs across 160+ countries
- 54 consecutive years of dividend increases with a 7%+ growth rate
- A fortress balance sheet (AA- rated, 43x interest coverage)
- Proven management that has navigated a pandemic windfall, a product recall, and a revenue cliff without missing a beat
- Guided 10% earnings growth in 2026 with margin expansion continuing
At ~$110, you're paying ~19x forward earnings for a business growing at 10%+ with visible catalysts for acceleration. That's not a once-in-a-decade steal, but it is a genuinely good price for a magnificent business. The intrinsic value math gives you a 10-30% margin of safety. The dividend yield at 2.3% is the highest it's been in years. The growth engine hasn't slowed — the market just got spooked by a single revenue miss.
Abbott's competitive moats are wide and widening. The healthcare tailwinds (aging populations, diabetes epidemic, emerging market growth) are structural and long-lasting. And the compounding math works: $110 invested today in a business growing earnings and dividends at 10%+ annually has a clear path to $200+ within a decade.
**Position:** Buy at current levels (~$110). Add aggressively if it dips toward the 52-week low (~$105). Hold for 10+ years.